Position:
Professor
Division:
Endocrinology & Metabolism
Education:
MB, BS St Bartholomew’s Hospital Medical College (University of London)
Recent Publications:
  •    Behn A, Ur E. The obesity epidemic and its cardiovascular consequences. Curr Opin Cardiol. 2006 Jul;21(4):353-60.
  • Ezzat S, Serri O, Chik CL, Johnson MD, Beauregard H, Marcovitz S, Nyomba BL, Ramirex JR, Ur E. Canadian consensus guidelines for the diagnosis and management of  acromegaly. Clin Invest Med. 2006 Feb;29(1):29-39.
  • Hegele RA, Ur E, Ransom TP, Cao H. A frameshift mutation in peroxisome-proliferator-activated receptor-gamma in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367). Clin Genet. 2006 Oct;70(4):360-2.
  • Kahn SE and ADOPT Study Group (Ur E). Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.  Diabetes, Vol. 55 (August 2006).
  • Shu DH, Ransom TP, O’Connell CM, Cos JL, Kaiser SM, Gee SA, Rowe RC, Ur E, Imran SA. Anemia is an independent risk for mortality after acute myocardial infarction in patients with and without diabetes.  Cardiovasc Diabetol. 2006 April 7;5:8.
  • Title LM, Ur E, Giddens K, McQueen MJ, Nassar BA. Folic acid improves endothelial dysfunction in type 2 diabetes-an effect independent of homocysteine-lowering. Vasc Med. 2006 May;11(2):101-9.
  • Ur E, Serri O, Legg K, Murphy LJ, Ezzat S. Canadian guidelines for the management of adult growth hormone deficiency. Clin Invest Med. 2006 Apr;29(2):83-90.
  • Wiesner G, Brown RE, Robertson GS, Imran SA, Ur E, Wilkinson M. Increased expression of the adipokine genes resistin and fasting0induced adipose factor in hypoxic/ischaemic mouse brain.  Neuroreport. 2006 July 31;17(11):1195-8.
  • Brown R, Imran SA, Belsham DD, Ur E, Wilkinson M.  Adipokine gene expression in a novel hypothalamic neuronal cell line: resistin-dependent regulation of fasting-induced adipose factor and SOCS-3. Neuroendocrinology 2007;85(4):232-41.
  • Brown RE, Imran SA, Ur E, Wilkinson M.  KiSS-1 mRNA in adipose tissue is regulated by sex hormones and food intake.  Mol Cell Endocrinol 2007;Nov 1.
  • Imran SA, Ur E, Clark DB.  Managing prolactin-secreting adenomas during pregnancy.  Can Fam Physician 2007 Apr;53(4):653-8. Review.
  • Lau DC, Douketis JD, Morrison KM, Hramiak IM, Shama AM, Ur E: Obesity Canada Clinical Practice Guidelines Expert Panel.  2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary].  CMAJ 2007 Apr 10;176(8):S1-13.
  • Wilkinson M, Brown R, Imran SA, Ur E.  Adipokine gene expression in brain and pituitary gland.  Neuroendocrinology 2007;86(3):191-209.
  • Action to Control Cardiovascular Risk in Diabetes Study Group (Ur E).  Effects of intensive glucose lowering in type 2 diabetes.N Engl J Med 2008;358(24):2545-59 .
  • ADVANCE Collaborative Group (Ur E). Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2008;358(24):2560-72.
  • Brown R, Imran SA, Ur E, Wilkinson M.  Valproic acid and CEBPa-mediated regualtio of adipokine gene expression in hypothalamic neurons and 3T3-L1 adipocytes.  Neuroendocrinology 2008;88(1):25-34.
  • Brown R, Thompson HJ, Imran SA, Ur E, Wilkinson M.  Traumatic brain injury induces adipokine gene expression in rat brain.  Neurosci Lett. 2008;432(1):73-8.
  • Chaturvedi N and DIRECT Programme Study Group (Ur E).  Lancet 2008;372(9647):1394-402.
  • Imran SA, Ur E. Atypical ketosis-prone diabetes. Can Fam Physician 2008;54(11):1553-4.
  • Kahn SE, (Ur E).  Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from a Diabetes Outcome Progression Trial (ADOPT).  Diabetes Care 2008;31(5):845-51.
  • MacKinnon NJ, Hartnell NR, Black EK, Dunbar P, Johnson J, Halliday-Mahar S, Pattar R, Ur, E.  Development of clinical indicators for type 2 diabetes.  CPJ/RPC March/April 2008;141(2):120-128.
  • Sjolie AK and DIRECT Programme Study Group (Ur E). Lancet 2008;18; 372(9647):1385-93.
  • Ur E, Chiasson J, Ransom T, Rowe R.  Definition, Classification and Diagnosis of Diabetes and Other Dysglycemic Categories.  Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
  • Ur E, Chiasson J, Ransom T, Rowe R.  Prevention of Diabetes.  Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
  • Ur E, Chiasson J, Ransom T, Rowe R.  Screening for Type 1 and Type 2 Diabetes.  Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
  • Kenangil G, Orken DN, Ur E, Forta H, Celik M.  The relation of testosterone levels with fatigue and apathy in Parkinson’s disease.  Clin Neurol Neurosurg. 2009 Jun;111(5):412-4.
  • Braga M, Casanova A, Dawson KG, Gerstein HC, Fitchett DH, Harris, SB, Honos G, McFarlane PA, Steele, A, Ur E at al.  Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada.  Can J Cardiology 2009 (In Press).
  • Imran SA, Fleetwood IG, O’Connell CM, Ransom TP, Mulroy LA, Ur E, Clarke DB.  Outcome of stereotactic radiotherapy for patients with uncontrolled acromegaly.  Can J Neurol Sci 2009;36(4):468-74.
  • Imran SA, Ransom TPP, Buth KJ, Clayton D, Al-Shehri B, Ur E et al.  Impact of admission serum glucose level on in-hospital outcomes following coronary artery bypass grafting surgery.  Can J Cardiology 2009 (In Press).
  • Mount DL, Feeney P, Fabricatore AN, Coday M, Bahnson J, Byington R, Phelan S, Wilmoth S, Knowler WC, Hramiak I, Osei K, Sweeney ME, Espeland MA; Look AHEAD and ACCORD Research Groups.  Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials.  Clin Trials. 2009 Oct;6(5):416-29.
  • Ur E, Langer A, Leither L, Rabkin S, Calciu C. On behalf of the CANACTFAST Study Investigators.  Achieving cholesterol targets by individualizing starting doses of statin according to baseline LDL-C and CHD Risk Category: The CANACTFAST Study. Can J Cardiology 2009 (In Press).
  • Cameron C, Coyle D, Ur E, Klarenbach S.  Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin.  CMAJ. 2010 Jan 12;182(1):28-34.
  • Ur E, Langer A, Rabkin SW, Calciu CD, Leiter LA, On Behalf Of The Canactfast Study Investigators .  Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: The CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study. Can J Cardiol. 2010 Feb;26(2):80-6.
  • Imran SA, Ransom TP, Buth KJ, Clayton D, Al-Shehri B, Ur E, Ali IS.  Impact of admission serum glucose level on in-hospital outcomes following coronary artery bypass grafting surgery.  Can J Cardiol. 2010 Mar;26(3):151-4.
  • Braga M, Casanova A, Teoh H, Dawson KC, Gerstein HC, Fitchett DH, Harris SB, Honos G, McFarlane PA, Steele A, Ur E, Yale JF, Langer A, Goodman SG, Leiter LA; Diabetes Registry to Improve Vascular Events (DRIVE) Investigators. Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada.  Can J Cardiol. 2010 Jun;26(6):297-302.
  • Teoh H, Braga MF, Casanova A, Drouin D, Goodman SG, Harris SB, Langer A, Tan MK, Ur E, Yan AT, Zinman B, Leiter LA; T2DM QUERI Investigators.  Patient age, ethnicity, medical history, and risk factor profile, but not drug insurance coverage, predict successful attainment of glycemic targets: Time 2 Do More Quality Enhancement Research Initiative (T2DM QUERI). Diabetes Care. 2010 Dec;33(12):2558-60.
  • Wilkinson M, Brown RE, Imran SA, Ur E.  Comment on: Kim et al. (2010) Hypothalamic Angptl4/Fiaf is a novel regulator of food intake and body weight. (Diabetes;59:2772-2780) Diabetes. 2011 Jan;60(1).
  • Cardiometabolic Risk Working Group: Executive Committee, Leiter LA, Fitchett DH, Gilbert RE, Gupta M, Mancini GB, McFarlane PA, Ross R, Teoh H, Verma S, Anand S, Camelon K, Chow CM, Cox JL, Després JP, Genest J, Harris SB, Lau DC, Lewanczuk R, Liu PP, Lonn EM, McPherson R, Poirier P, Qaadri S, Rabasa-Lhoret R, Rabkin SW, Sharma AM, Steele AW, Stone JA, Tardif JC, Tobe S, Ur E. Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). Can  J Cardiol. 2011 Mar-Apr;27(2):124-31. Review.
  • Porta M, Hainer JW, Jansson SO, Malm A, Bilous R, Chaturvedi N, Fuller JH, Klein R, Orchard T, Parving HH, Sjølie AK; DIRECT Study Group. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.Diabetologia. 2011 Jun;54(6):1298-303.
  • Klarenbach S, Cameron C, Singh, S, Ur, E. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. CMAJ Oct 2011.
  • ACCORD Study Group, (Ur E). Long-term effects of intensive glucose lowering on cardiovascular outcomes.  N Engl J Med. 2011 Mar 3;364(9):818-28. Lancet Neurol. 2011 Nov;10(11):969-77.
  • Punthakee Z, Bosch J, Dagenais G, Diaz R, Holman R, Probstfield JL, Ramachandran A, Riddle MC, Rydén LE, Zinman B, Afzal R, Yusuf S, Gerstein HC; TIDE Trial Investigators. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.  Diabetologia. 2012 Jan;55(1):36-45.
  • ACCORD MIND investigators (Ur E). Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy.
  • Al Malki M, Chesover AD, Johnson MD, Wilkins GE, Maguire, JA, Ur E. Chacterization of management and outcomes of patients with acromegaly in Vancouver over 30 years.  Clin Inv Med 2012; 35(1):E27-E33.